Loading…
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents
The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the...
Saved in:
| Published in: | Current oncology reports 2005-03, Vol.7 (2), p.116-122 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3 |
| container_end_page | 122 |
| container_issue | 2 |
| container_start_page | 116 |
| container_title | Current oncology reports |
| container_volume | 7 |
| creator | Desai, Apurva A Stadler, Walter M |
| description | The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development. |
| doi_str_mv | 10.1007/s11912-005-0037-6 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67441845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67441845</sourcerecordid><originalsourceid>FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3</originalsourceid><addsrcrecordid>eNpFkEtLxDAUhYMozjj6A9xIVu6quc2z7kR8waAbXbgKaZqO0bYZk86A_96UGXBxX3DO4fIhdA7kCgiR1wmggrIghOeishAHaA6cskKUojqc9pIWVFZkhk5S-iKkJESRYzQDLkFWjM_Rx0vYug5_-8Ekh_3w6Ws_hpjyiqMbTIet63Iz0foh9OYGr2NYRZeS3zrcuGwO694NIw4tTqMZvcVmle90io5a0yV3tp8L9P5w_3b3VCxfH5_vbpeFLYGNBdCaW2uEVJZZaEpOFFPKUgvMNYq2NZMtr7iFUlDVOGFB1oI1tGFOKlLWdIEud7n5sZ-NS6PufZqeNoMLm6SFZAwU41kIO6GNIaXoWr2OvjfxVwPRE0-946kzTz3x1CJ7Lvbhm7p3zb9jD5D-AVJPcWQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67441845</pqid></control><display><type>article</type><title>Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents</title><source>Springer Nature</source><creator>Desai, Apurva A ; Stadler, Walter M</creator><creatorcontrib>Desai, Apurva A ; Stadler, Walter M</creatorcontrib><description>The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-005-0037-6</identifier><identifier>PMID: 15717945</identifier><language>eng</language><publisher>United States</publisher><subject>Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Benzenesulfonates - pharmacology ; Benzenesulfonates - therapeutic use ; Bevacizumab ; Carcinoma, Renal Cell - drug therapy ; Clinical Trials as Topic ; Enzyme Inhibitors - therapeutic use ; Humans ; Indoles - pharmacology ; Indoles - therapeutic use ; Kidney Neoplasms - drug therapy ; Niacinamide - analogs & derivatives ; Phenylurea Compounds ; Protein Kinase Inhibitors - therapeutic use ; Pyridines - pharmacology ; Pyridines - therapeutic use ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - therapeutic use</subject><ispartof>Current oncology reports, 2005-03, Vol.7 (2), p.116-122</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3</citedby><cites>FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15717945$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Desai, Apurva A</creatorcontrib><creatorcontrib>Stadler, Walter M</creatorcontrib><title>Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><description>The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.</description><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzenesulfonates - pharmacology</subject><subject>Benzenesulfonates - therapeutic use</subject><subject>Bevacizumab</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Clinical Trials as Topic</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Phenylurea Compounds</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyridines - pharmacology</subject><subject>Pyridines - therapeutic use</subject><subject>Pyrroles - pharmacology</subject><subject>Pyrroles - therapeutic use</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - therapeutic use</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpFkEtLxDAUhYMozjj6A9xIVu6quc2z7kR8waAbXbgKaZqO0bYZk86A_96UGXBxX3DO4fIhdA7kCgiR1wmggrIghOeishAHaA6cskKUojqc9pIWVFZkhk5S-iKkJESRYzQDLkFWjM_Rx0vYug5_-8Ekh_3w6Ws_hpjyiqMbTIet63Iz0foh9OYGr2NYRZeS3zrcuGwO694NIw4tTqMZvcVmle90io5a0yV3tp8L9P5w_3b3VCxfH5_vbpeFLYGNBdCaW2uEVJZZaEpOFFPKUgvMNYq2NZMtr7iFUlDVOGFB1oI1tGFOKlLWdIEud7n5sZ-NS6PufZqeNoMLm6SFZAwU41kIO6GNIaXoWr2OvjfxVwPRE0-946kzTz3x1CJ7Lvbhm7p3zb9jD5D-AVJPcWQ</recordid><startdate>200503</startdate><enddate>200503</enddate><creator>Desai, Apurva A</creator><creator>Stadler, Walter M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200503</creationdate><title>Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents</title><author>Desai, Apurva A ; Stadler, Walter M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzenesulfonates - pharmacology</topic><topic>Benzenesulfonates - therapeutic use</topic><topic>Bevacizumab</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Clinical Trials as Topic</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Phenylurea Compounds</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyridines - pharmacology</topic><topic>Pyridines - therapeutic use</topic><topic>Pyrroles - pharmacology</topic><topic>Pyrroles - therapeutic use</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Desai, Apurva A</creatorcontrib><creatorcontrib>Stadler, Walter M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Desai, Apurva A</au><au>Stadler, Walter M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents</atitle><jtitle>Current oncology reports</jtitle><addtitle>Curr Oncol Rep</addtitle><date>2005-03</date><risdate>2005</risdate><volume>7</volume><issue>2</issue><spage>116</spage><epage>122</epage><pages>116-122</pages><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>The rapidly expanding knowledge regarding neoplastic diseases is providing a plethora of new targets for drug discovery and development as exemplified by recent data in renal cell carcinoma. The initial experience with molecularly "targeted" agents has demonstrated that development of the newer non-cytotoxic agents will provide unique challenges requiring modification of many traditional drug development concepts and methods. We discuss recently reported data from a few renal cell carcinoma trials with putative cytostatic agents and highlight issues that need to be addressed for efficient development of cytostatic agents during various phases of clinical development.</abstract><cop>United States</cop><pmid>15717945</pmid><doi>10.1007/s11912-005-0037-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3790 |
| ispartof | Current oncology reports, 2005-03, Vol.7 (2), p.116-122 |
| issn | 1523-3790 1534-6269 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67441845 |
| source | Springer Nature |
| subjects | Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Benzenesulfonates - pharmacology Benzenesulfonates - therapeutic use Bevacizumab Carcinoma, Renal Cell - drug therapy Clinical Trials as Topic Enzyme Inhibitors - therapeutic use Humans Indoles - pharmacology Indoles - therapeutic use Kidney Neoplasms - drug therapy Niacinamide - analogs & derivatives Phenylurea Compounds Protein Kinase Inhibitors - therapeutic use Pyridines - pharmacology Pyridines - therapeutic use Pyrroles - pharmacology Pyrroles - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - therapeutic use |
| title | Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A16%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20kinase%20inhibitors%20in%20renal%20cell%20carcinoma:%20progressive%20development%20of%20static%20agents&rft.jtitle=Current%20oncology%20reports&rft.au=Desai,%20Apurva%20A&rft.date=2005-03&rft.volume=7&rft.issue=2&rft.spage=116&rft.epage=122&rft.pages=116-122&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-005-0037-6&rft_dat=%3Cproquest_cross%3E67441845%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c214t-13b5cca678c4c1d2508488c3c14ed83fb47f595c12638de6c17b64d3d4e7802b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67441845&rft_id=info:pmid/15717945&rfr_iscdi=true |